Publicador de contenidos



Towards the interruption of transmission of soil-transmitted helminths

Foto: CDC
Oct 01, 2018 - Sep 01, 2022
Jose Muñoz
EDCTP (European & Developing Countries Clinical Trial Partnership)

The current World Health Organization (WHO) control strategy for Soil-Transmitted Helminths (STH) emphasizes morbidity control through mass drug administration with albendazole or mebendazole, mainly targeting preschool and school-aged children in endemic areas. Increasing concerns have been raised about the success of these monotherapy strategies: 1) whilst albendazole is still efficacious against Ascaris lumbricoides and hookworm, a low and decreasing efficacy against Trichuris trichiura is observed, and none of these strategies is effective against Strongyloides stercoralis; 2) the use of widespread monotherapy could lead to the emergence of albendazole resistance. Modeling studies predict a huge impact on years lived with disability and economic productivity, if these strategies remain unchanged.

Ivermectin has shown an enhanced activity against T. trichiura when combined with albendazole, and is considered the drug of choice against strongyloidiasis and other parasitic infections. Adding ivermectin to albendazole would increase efficacy of the interventions, and decrease the possibility of emergence of resistance, as recently suggested by WHO.


The main goal of the STOP project is to develop and test the safety and efficacy of a fixed-dose co-formulation of ivermectin and albendazole against STHs, as a single dose and a three-dose regimen, compared to a single dose of albendazole in a phase III clinical trial.

The project will include capacity building and networking activities. Besides microscopy-based procedures, parasite DNA detecting techniques (PCR) will be used and validated as markers of treatment response. Modeling studies will evaluate the potential impact on transmission and economic benefits of the new treatment regimen. The scientific results will be presented to the scientific community, local governments and other implementation actors and stakeholders.

Previous collaborations of members of this consortium developed and tested the safety of a fixed high dose of ivermectin, as a first step towards the fixed-dose combination with albendazole. This consortium integrates complementary expertise in drug development, manufacture and regulatory processes with a pharmaceutical company, with expertise in parasitology, veterinary, epidemiology and public health. This places us in a unique situation to progress to the regulatory approval and market authorization by health authorities (WHO and EMA) and to advocate for policy changes among the different stakeholders, while ensuring a continuous supply of ivermectin for the control of several Neglected Tropical Diseases.

The proposed fixed-dose formulation represents a promising tool to alleviate the burden of STH morbidity, help stop STH transmission and ultimately contribute to the achievement of the SDGs.

Total funding


Nuestro equipo

Principal investigator

  • Jose Muñoz Gutiérrez
    Jose Muñoz Gutiérrez

ISGlobal team

Otros proyectos

Ver proyectos pasados


Combatiendo la Resistencia Bacteriana en Europa


Development of Novel Gastrointestinal Biomarkers for Use in HIV Incidence Determination in a Sub-Saharan African Setting


Combatting Bacterial Resistance in Europe - Carbapenem Resistance


Improving Maternal and Infant Health by reducing malaria risks in African women: evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women


Integrating and decentralizing diabetes and hypertension services in Africa


Improving Care through Azithromycin Research for Infants in Africa


Predicting the Future: Incipient Tuberculosis


Large Clinical Trial in Africa on the Treatment of Mild Cases of COVID-19


Evaluating a new stool based qPCR for diagnosis of tuberculosis in children and people living with HIV


Reconnecting Transmission to Global Tuberculosis Control by Mapping Pathogen Transmission Events to Host Infection Status


Quantifiable stool-based TB PCR to Improve Diagnostics and Treatment Monitoring


ENDing COVID-19 Variants Of concern through Cohort studies (END-VOC)


Digital Twins Enabled Indoor Air Quality Management for Healthy Living


Community knowledge generation through scientific culture, urban ecology and art


Building Scalable Pathogen Genomic Epidemiology in Ethiopia

Hepatitis C Free Baleares

Eliminating hepatitis C on the Balearic Islands (Mallorca, Menorca and Ibiza): a study in governmental and non-governmental addiction service centres, a mobile methadone unit and a prison to test and link people who use drugs to HCV care.


Nuevas moléculas de oro coordinadas con flavonoides contra bacterias patógenas multirresistentes prioritarias


Nuevas Herramientas para el Diagnóstico y la Evaluación del Paciente con Enfermedad de Chagas

Estudio inmunológico de la vacuna RTS,S

Estudio de correlatos de protección frente a la malaria después de la vacunación con RTS,S/AS01E: Una evaluación inmunológica exhaustiva en el ensayo clínico de Fase III, doble ciego, aleatorizado, multicéntrico con un grupo control

Control of Leishmaniasis. From bench to bedside and community


Grup de recerca en patología importada i malaties emergents i re-emergents


Nuevos regímenes de quimioterapia y biomarcadores para la enfermedad de Chagas


Unravelling Disease Tolerance and Host Resistance in Afebrile 'P. falciparum' Infections: a Prospective Study in Mozambican Adults


Administración masiva y focal de fármacos antimaláricos para avanzar hacia la eliminación de la malaria en Mozambique: acelerando la implementación de programas y políticas


MULTIple doses of IPTi Proposal: a Lifesaving high Yield intervention


Citizens engagement digital platform for collective intelligence in pandemics


Novel organ-on-a-chip technology to study extracellular vesicles-mediated cryptic infections in Plasmodium vivax malaria


Identifying Severe Malaria with a new Aptamer-based Rapid diagnostic Test


Transcriptional regulation of adaptation and developmental decisions in malaria parasites: from epigenetic variation to directed transcriptional responses


P. falciparum genomic intelligence in Mozambique


Broad One Health Endectocide-based Malaria Intervention in Africa


Mechanisms of the transcriptional responses to changes in the environment in the malaria parasite Plasmodium falciparum


Extracellular Vesicles as Intercellular Communicators and Biomarkers of Cryptic Erythrocytic Infections in Plasmodium vivax malaria


Unravelling the heterogoneity and function of monocytes in vaccination and immunity to malaria


Insight on climate and social participatory research for integral management of vectorborne zoonosis caused by Trypanosoma cruzi and Leishmania spp. in the Bolivian Gran Chaco.


Social affairs and sex in P. falciparum: implications for malaria elimination

MENA Migrant Health

Transforming data collection and surveillance to drive migrant health research, care and policy


La Alianza Científica para la Erradicación de la Malaria (MESA) tiene como objetivo avanzar en la ciencia de la erradicación de la malaria.